- Home
- WRN vs NYXH Comparison
WRN vs NYXH Comparison
Compare WRN & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRN
- NYXH
- Stock Information
- Founded
- WRN 2006
- NYXH 2009
- Country
- WRN Canada
- NYXH Belgium
- Employees
- WRN N/A
- NYXH N/A
- Industry
- WRN Metal Mining
- NYXH Medical/Dental Instruments
- Sector
- WRN Basic Materials
- NYXH Health Care
- Exchange
- WRN Nasdaq
- NYXH Nasdaq
- Market Cap
- WRN 228.0M
- NYXH 222.3M
- IPO Year
- WRN N/A
- NYXH 2021
- Fundamental
- Price
- WRN $1.23
- NYXH $7.75
- Analyst Decision
- WRN Strong Buy
- NYXH Strong Buy
- Analyst Count
- WRN 1
- NYXH 4
- Target Price
- WRN $4.00
- NYXH $14.50
- AVG Volume (30 Days)
- WRN 421.9K
- NYXH 76.5K
- Earning Date
- WRN 08-08-2025
- NYXH 08-05-2025
- Dividend Yield
- WRN N/A
- NYXH N/A
- EPS Growth
- WRN N/A
- NYXH N/A
- EPS
- WRN N/A
- NYXH N/A
- Revenue
- WRN N/A
- NYXH $4,716,818.00
- Revenue This Year
- WRN N/A
- NYXH $323.07
- Revenue Next Year
- WRN N/A
- NYXH $204.30
- P/E Ratio
- WRN N/A
- NYXH N/A
- Revenue Growth
- WRN N/A
- NYXH N/A
- 52 Week Low
- WRN $0.90
- NYXH $5.55
- 52 Week High
- WRN $1.42
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- WRN 57.42
- NYXH 62.70
- Support Level
- WRN $1.32
- NYXH $7.45
- Resistance Level
- WRN $1.39
- NYXH $7.85
- Average True Range (ATR)
- WRN 0.06
- NYXH 0.27
- MACD
- WRN 0.01
- NYXH -0.02
- Stochastic Oscillator
- WRN 59.68
- NYXH 97.33
About WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.